Daniel Lang, a partner in Goodwin’s Technology Companies & Life Sciences group, concentrates on startup, financing, M&A, general corporate and securities law matters, and has significant experience in company formations; seed, venture and growth financings; mergers and acquisitions; IPOs and other capital markets transactions; SEC compliance and corporate governance. Mr. Lang represents public and private companies in diverse industries such as e-commerce, digital media, advertising technology, consumer and enterprise software, AI, health and wellness, health technology, biotechnology and diagnostics, as well as the investors and financial services firms that focus on these sectors. He has advised companies through every stage of the corporate life cycle – from entity selection and initial financing through successful initial public offering or acquisition.

Mr. Lang was recognized as a New York Metro Rising Star by Super Lawyers in 2014-2017. 





Mr. Lang’s representative clients include public companies: Foundation Medicine, Chiasma, Allena Pharmaceuticals and Precipio; private companies: Glossier, Hubble Contacts, Thrive Global, Paperless Post, Pond5, Aircall, Avvir, Celtra, Revivn, Landover Wireless, LifeCo, Noteworth, Megaphone TV, Proclivity Media, Zive, Codiak BioSciences, Oculus Health, Aspire Health, Syntimmune, TARA Biosystems, EpicentRx and Linkwell Health; and investment funds: Vivo Capital, Glasswing Ventures, Macquarie Capital, Urgent VC, InterWest Partners and Hermed Capital.

Representative Matters



Public Company Transactions
  • Foundation Medicine, in its (i) $120 million initial public offering, (ii) collaboration and equity transaction with Roche, with total value in excess of $1 billion and (iii) sale of the remaining minority interest to Roche for $2.4 billion
  • Ocera Therapeutics, in its (i) acquisition by Mallickrodt for up to $117 million in upfront cash and contingent (CVR) consideration, (ii) $28 million PIPE financing, (iii) $25 million public offering and (iv) $25 million “at the market” offering facility
  • Allena Pharmaceuticals in its $75 million initial public offering
  • Chiasma in its $102 million initial public offering
  • J.P. Morgan in a $200 million convertible note offering of Intrexon
  • J.P. Morgan and Barclays Capital in the $184 million initial public offering of Intrexon
  • J.P. Morgan in the $116 million follow-on offering of Intrexon
  • JMP Securities in the $230 million follow-on offering of Intrexon
  • Cantor Fitzgerald in a $200 million “at the market” offering facility for Intrexon
  • Vivo Capital in investments in BioPharmX, Strongbridge Pharma, Kadmon and MEI Pharma
  • Intralinks, Tranzyme and Tengion in their initial public offerings
Mergers and Acquisitions
  • Syntimmune in its acquisition by Alexion Pharmaceuticals
  • Aspire Health in its acquisition by Anthem
  • Orchard Platform in its acquisition by Kabbage
  • Glossier in its acquisition of Dynamo E-Media 
  • Thar Pharmaceuticals in its acquisition by Grünenthal
  • Songza in its acquisition by Google
  • M5 Networks in its acquisition by ShorTel
  • XGraph in its acquisition by Add This (formerly Clearspring)
  • Fidelis Security Systems in its acquisition by General Dynamics
  • Nomi Technologies in its acquisition by Brickstream
  • Tagman in its acquisition by Ensighten
  • EveryScreen Media in acquisition by Media6Degrees
Private Financings
  • Vivo Capital in various public and private investments
  • Macquarie Capital in various investments and strategic collaborations 
  • Glossier in various financings with participation by Institutional Venture Partners, Thrive Capital, Forerunner Ventures and Index Ventures 
  • Hubble Contacts in various financings with participation by First Mark Capital, Two River, Wildcat Capital Management, Founders Fund, Greycroft and Colgate
  • Aircall in various financings with participation by Draper Esprit, Next World Capital, Balderton Capital and eFounders
  • Codiak BioSciences in various financings with participation by ARCH Venture Partners, Flagship Pioneering, Fidelity, Alaska Permanent Fund, Alexandria Venture Investments, Qatar Investment Authority, Tavistock Group, Sirona Capital, EcoR1 Capital and Casdin Capital
  • Celtra in various financings with participation by WPP, Unilever, Grandbanks Capital and Fairhaven Capital
  • Syntimmune in its $50.0 million financing led by Apple Tree Partners
  • PatientBank in its $2.2 million financing led by General Catalyst and Khosla Ventures with participation by SV Angels, Spectrum 28 and Data Collective
  • Allena Pharmaceuticals in its $53 million financing led by Partner Fund Management, Fidelity and Wellington
  • Precision Biologics in its $50 million financing by NantWorks
  • Orchard Platform in its $30 million financing led by Thrive Capital, Spark Capital and Canaan Partners
  • Linkwell Health in various financings with participation by HLM Venture Partners and Spark Capital
  • Even Financial in its $2.8 million financing led by Canaan Partners and Lerer Hippeau Ventures
  • Pond5 in its $61 million financing by Accel Partners and Stripes Group
  • Paperless Post in its $25 million financing led by August Capital
  • Megaphone TV in its $4.3 million financing led by Softbank Korea
  • Nomi Technologies in its $10 million financing by Accel Partners, First Round Capital, Greycroft and Forerunner Ventures
  • Glasswing Ventures in various private investments, including Talla, ZyloTech, Inrupt and ChaosSearch
  • InterWest and Orbimed, as lead investors, in a $32 million investment in Avedro
  • Hermed Capital in its investments in Prognos and Spineology
Professional Activities

Mr. Lang is a frequent lecturer at the Cardozo Tech Law Start Up Clinic, Columbia Business School, Columbia Law School, Cornell Tech and eLab NYC on venture financings and other elements of start-up law.


Mr. Lang was named a New York Metro Rising Star by Super Lawyers in 2014-2017. In law school, Mr. Lang was an articles editor of the Cardozo Law Review.

In The News









J.D., 2006
Benjamin N. Cardozo School of Law

(cum laude)

B.A., 2003
Tufts University

(magna cum laude)



New York
New Jersey
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique